FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study
about
Micro-RNAs as potential new molecular biomarkers in oncology: have they reached relevance for the clinical imaging sciences?Insights on the functional interactions between miRNAs and copy number variations in the aging brainThe prognostic and functional role of microRNAs in acute myeloid leukemiaTET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia.Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemiaOutcome of older patients with acute myeloid leukemia: an analysis of SEER data over 3 decades.High expression of IGFBP2 is associated with chemoresistance in adult acute myeloid leukemiaOutcomes of UCB transplantation are comparable in FLT3+ AML: results of CIBMTR, EUROCORD and EBMT collaborative analysis.miR-155 promotes FLT3-ITD-induced myeloproliferative disease through inhibition of the interferon responseInteractions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)Emerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemiaMAGIA²: from miRNA and genes expression data integrative analysis to microRNA-transcription factor mixed regulatory circuits (2012 update).Clinical features of de novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations.The role of microRNAs in acute myeloid leukemia.Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia.MiR-101 and miR-144 regulate the expression of the CFTR chloride channel in the lungIdentification of circulating microRNAs as potential biomarkers for detecting acute myeloid leukemia.Incidence and prognostic impact of DNMT3A mutations in Korean normal karyotype acute myeloid leukemia patients.Expression and prognostic impact of lncRNAs in acute myeloid leukemia.Repression of tumor suppressor miR-451 is essential for NOTCH1-induced oncogenesis in T-ALL.Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemiaAssociation between DNMT3A mutations and prognosis of adults with de novo acute myeloid leukemia: a systematic review and meta-analysisClinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.Integrated genomic profiling, therapy response, and survival in adult acute myelogenous leukemiaCirculating MicroRNAs as Minimally Invasive Biomarkers for Cancer Theragnosis and Prognosis.Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in newly diagnosed elderly patients with acute myeloid leukemiaLow expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia.Transcriptome sequencing reveals CHD1 as a novel fusion partner of RUNX1 in acute myeloid leukemia with t(5;21)(q21;q22).Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes: An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation.Genome-Wide CRISPR-Cas9 Screen Identifies MicroRNAs That Regulate Myeloid Leukemia Cell Growth.Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia.Outcome of older adults with cytogenetically normal AML (CN-AML) and FLT3 mutationsMicroRNAs in Acute Myeloid Leukemia and Other Blood Disorders.Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia.Overexpression of ATP1B1 predicts an adverse prognosis in cytogenetically normal acute myeloid leukemiaAcute myeloid leukaemia: optimal management and recent developments.miR-9 is an essential oncogenic microRNA specifically overexpressed in mixed lineage leukemia-rearranged leukemia.Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients
P2860
Q27005811-02B75A5C-2108-4D3A-9254-BB45057CBFB3Q27024584-2B964A0F-05B3-48EB-8E67-FB20790A73E1Q27693865-1E8BA28A-FF08-4DF6-950C-504106E96542Q27851621-06BE3A71-BC6B-458E-8CC1-F7267B730BFAQ27851679-0FADED54-2540-4104-8E21-05F37AB736C2Q27851689-F1D50878-CEA5-4DCF-AFAA-0E7B15F5AA08Q27851713-F512101F-BCC8-4557-BD74-D5E3BD898C2DQ30620658-6B8289B6-7037-42B2-B72B-DFFFF86F2053Q33623126-E0D2B873-E7EA-41AB-AF02-93FE645F2250Q33774504-BED0FD91-35A0-491C-AC42-9A4ECD7430EFQ33782332-F376ACD8-618C-4AA5-BECC-526183581321Q33840247-22E7C38C-ACFC-4278-9C27-9F8D6BE07C14Q34004131-4CF3DB71-D04F-4BA4-B43F-3234B3D8ECBDQ34278592-DA4557BE-5618-4E21-A9E8-D9BE900C5864Q34340438-5FD622ED-51E0-449F-87E0-2EE6F59FA921Q34389746-13BB51DF-400B-411D-9724-D8AA55B2DB16Q34476246-ED4D1EE4-21FF-4C24-91E8-7B61EEC87358Q34505995-EC31E112-AE3B-43F6-8EA1-9262397698EFQ34599349-8AA7A676-3D44-46FD-9D0E-9EF0285705CEQ34667807-AF3BACCC-BEE7-4C75-A68F-12E20AF295C6Q34831106-DD8119E4-1B77-444B-AE01-6109E8043B69Q35102264-5E5D2454-D98A-494E-96C7-293B993BEC1DQ35152173-6085464E-EDD6-4427-979B-E7606F62A386Q35189447-8222A739-E980-4F89-9594-AAE3AD0F0C1CQ35265946-3010328D-C18D-4B81-A5FB-9CA4A13AF13EQ35562821-DF8D89A2-2101-4EC8-86EE-15D40B86C3F5Q35710995-248864DF-7828-4BF2-B48F-54DC630F7636Q35742564-F3B8C220-8742-41D4-803C-264B70B35A2EQ35794120-BA3E493C-63CE-4460-A568-7671D05069F9Q35800581-D1C82BA1-F9F1-4342-9557-7435CA90A3DEQ35863989-6CE35DDC-DD8D-4CFE-BDF2-80D508BE3D8AQ35990849-4280CEBB-7AF2-4BD7-A4C6-D3DDAD0EC943Q36057877-EF409A2B-ECB7-4068-95A8-76294546BE04Q36400942-6D396D9E-D4BC-414F-99F3-5D600329EFB5Q36422143-3E90380D-75D7-4B71-BA53-150FA619095EQ36758390-45FE9747-F150-4774-B7FA-1DC2E445B650Q36771874-C6F13766-540C-4BB1-A917-E88744EC58C4Q36914091-07C6C9BC-7ACD-4478-8D51-E663E20F92B7Q37010564-5164FEA9-66D9-4D56-8BC4-8D08215B676FQ37065843-51547886-CD62-4D6A-9C44-86207704B723
P2860
FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study
description
2010 nî lūn-bûn
@nan
2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
FLT3 internal tandem duplicati ...... cer and Leukemia Group B study
@ast
FLT3 internal tandem duplicati ...... cer and Leukemia Group B study
@en
FLT3 internal tandem duplicati ...... cer and Leukemia Group B study
@nl
type
label
FLT3 internal tandem duplicati ...... cer and Leukemia Group B study
@ast
FLT3 internal tandem duplicati ...... cer and Leukemia Group B study
@en
FLT3 internal tandem duplicati ...... cer and Leukemia Group B study
@nl
prefLabel
FLT3 internal tandem duplicati ...... cer and Leukemia Group B study
@ast
FLT3 internal tandem duplicati ...... cer and Leukemia Group B study
@en
FLT3 internal tandem duplicati ...... cer and Leukemia Group B study
@nl
P2093
P2860
P50
P921
P1433
P1476
FLT3 internal tandem duplicati ...... cer and Leukemia Group B study
@en
P2093
Andrew J Carroll
Bayard L Powell
Dean Margeson
Heiko Becker
Jonathan E Kolitz
Joseph O Moore
Kelsi B Holland
Maria R Baer
Meir Wetzler
P2860
P304
P356
10.1182/BLOOD-2010-05-283648
P407
P50
P577
2010-07-23T00:00:00Z